Blog
RSS FeedPosted by Michael Wonder on 12 Apr 2021
ICER to use Aetion observational RWE to update value assessment of treatments for hereditary angioedema
12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost ...
Posted by Michael Wonder on 08 Apr 2021
ICER to assess treatment for hypertrophic cardiomyopathy
8 April 2021 - Report will be subject of CTAF meeting in October 2021; draft scoping document open to public comment ...
Posted by Michael Wonder on 05 Apr 2021
ICER publishes evidence report on therapies for multiple myeloma
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
Posted by Michael Wonder on 17 Mar 2021
ICER analyses are flawed, undervalue life saving medicines, and are biased toward price controls, finds new PRI brief
17 March 2021 - A commonly-used analysis to determine a medicine's value is based on flawed methodologies that would diminish ...
Posted by Michael Wonder on 15 Mar 2021
Aurinia announces positive cost effectiveness assessment of Lupkynis (voclosporin) in latest ICER draft evidence report
15 March 2021 -Aurinia Pharmaceuticals today announced a favorable assessment regarding the cost-effectiveness and value of Lupkynis (voclosporin), based on ...
Posted by Michael Wonder on 15 Mar 2021
ICER to assess treatments for myasthenia gravis
15 March 2021 - Report will be subject of New England CEPAC meeting in September 2021; draft scoping document open ...
Posted by Michael Wonder on 13 Mar 2021
ICER publishes evidence report on therapies for lupus nephritis
12 March 2021 - The evidence suggests belimumab and voclosporin represent important new treatment options for lupus nephritis; there is ...
Posted by Michael Wonder on 11 Mar 2021
The broader societal impacts of COVID-19 and the growing importance of capturing these in health economic analyses
9 March 2021 - The rapid spread of the current COVID-19 pandemic has affected societies worldwide, leading to excess mortality, long ...
Posted by Michael Wonder on 05 Mar 2021
ICER publishes final evidence report and policy recommendations on roxadustat
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
Posted by Michael Wonder on 02 Mar 2021
What could Biden’s possible bid for a national health technology assessment entity look like?
2 March 2021 - The U.S. has never had a publicly funded, independent health technology assessment organisation to evaluate prescription drugs, ...
Posted by Michael Wonder on 02 Mar 2021
ICER publishes Final Evidence Report and policy recommendations on new therapies for high cholesterol
2 March 2021 - For bempedoic acid, independent appraisal committee votes that the evidence is not adequate to demonstrate a net ...
Posted by Michael Wonder on 12 Feb 2021
ICER releases draft evidence report on therapies for multiple myeloma
11 February 2021 - Public comment period now open until March 11, 2021; Requests to make oral comment during public meeting ...
Posted by Michael Wonder on 10 Feb 2021
Due to aducanumab’s new PDUFA date, ICER extends timeline for Alzheimer’s disease assessment
10 February 2021 - The ICER announced today it has extended its timeline for assessing the comparative clinical effectiveness and ...
Posted by Michael Wonder on 09 Feb 2021
The Biden administration needs to look beyond ICER for evaluating drug therapies
9 February 2021 - As breakthrough drugs stream out of biopharmaceutical laboratories, how much they should cost and who will ...
Posted by Michael Wonder on 28 Jan 2021
ICER publishes evidence report on roxadustat for treating anaemia in chronic kidney disease
28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...